Transcrocetinate
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Transcrocetinate
- DrugBank Accession Number
- DB05974
- Background
Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Transcrocetinate (DB05974)
- Weight
- Average: 328.408
Monoisotopic: 328.167459253 - Chemical Formula
- C20H24O4
- Synonyms
- 8,8'-diapo-8,8'-carotenedioic acid
- 8,8'-diapo-ψ,ψ-carotenedioic acid
- 8,8'-diapocarotenedioic acid
- Crocetin
- trans-crocetin
Pharmacology
- Indication
Investigated for use/treatment in cancer/tumors (unspecified), hemorrhage, hypoxia, respiratory failure, and strokes.
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
Trans sodium crocetinate is a novel drug, which has been shown to increase whole-body oxygen consumption during hemorrhagic shock. It works by increasing the diffusion rate of oxygen through plasma rather than on a specific symptom of hemorrhagic shock and has been suggested as a general treatment for hypoxemia. Thus it could also be beneficial for treating respiratory insufficiencies.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareDarbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Transcrocetinate. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Transcrocetinate. Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Transcrocetinate. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Transcrocetinate. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Transcrocetinate sodium YP57637WMX 591230-99-8 RMDMBHQVNHQDDD-VFWKRBOSSA-L
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 20TC155L9C
- CAS number
- 27876-94-4
- InChI Key
- PANKHBYNKQNAHN-MQQNZMFNSA-N
- InChI
- InChI=1S/C20H24O4/c1-15(11-7-13-17(3)19(21)22)9-5-6-10-16(2)12-8-14-18(4)20(23)24/h5-14H,1-4H3,(H,21,22)(H,23,24)/b6-5+,11-7+,12-8+,15-9+,16-10+,17-13+,18-14+
- IUPAC Name
- (2E,4E,6E,8E,10E,12E,14E)-2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioic acid
- SMILES
- C\C(\C=C\C=C(/C)C(O)=O)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O
References
- General References
- Giassi LJ, Poynter AK, Gainer JL: Trans sodium crocetinate for hemorrhagic shock: effect of time delay in initiating therapy. Shock. 2002 Dec;18(6):585-8. [Article]
- Gainer JL, Stennett AK, Murray RJ: The effect of trans sodium crocetinate (TSC) in a rat oleic acid model of acute lung injury. Pulm Pharmacol Ther. 2005;18(3):213-6. Epub 2005 Jan 22. [Article]
- External Links
- KEGG Compound
- C08588
- ChemSpider
- 4444644
- BindingDB
- 50269617
- ChEBI
- 3918
- ChEMBL
- CHEMBL464792
- ZINC
- ZINC000004097701
- Wikipedia
- Crocetin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Glioblastomas 1 2 Terminated Treatment Stroke, Acute 1 1 Recruiting Basic Science Healthy Volunteers 1 1 Terminated Basic Science High Grade Glioma (HGG) 1 1, 2 Completed Treatment GBM / Glioblastomas / Gliomas 1 1, 2 Completed Treatment Intermittent Claudication 1 1, 2 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) / SARS-CoV-2 (Covid19) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00558 mg/mL ALOGPS logP 4.54 ALOGPS logP 4.4 ChemAxon logS -4.8 ALOGPS pKa (Strongest Acidic) 4.41 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 74.6 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 103.8 m3·mol-1 ChemAxon Polarizability 38.07 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on November 18, 2007 18:29 / Updated on June 12, 2020 16:52